Adenovirus (Ad) is used extensively for construction of viral vectors, most commonly with deletion in its E1 and/or E3 genomic regions. Previously, our attempts to insert envelope proteins (Env) of HIV-1 into such vectors based on chimpanzee-derived Ad (AdC) viruses were thwarted. Here, we describe that genetic instability of an E1- and E3-deleted AdC vector of serotype C6 expressing Env of HIV-1 can be overcome by reinsertion of E3 sequences with anti-apoptotic activities. This partial E3 deletion presumably delays premature death of HEK-293 packaging cell lines due to Env-induced cell apoptosis. The same partial E3 deletion also allows for the generation of stable glycoprotein 140 (gp140)- and gp160-expressing Ad vectors based on AdC7, a distinct AdC serotype. Env-expressing AdC vectors containing the partial E3 deletion are genetically stable upon serial cell culture passaging, produce yields comparable to those of other AdC vectors, and induce transgene product–specific antibody responses in mice. A partial E3 deletion thereby allows expansion of the repertoire of transgenes that can be expressed by Ad vectors.
AppaiahgariMB, VratiS. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther, 2015; 15:337–351.
3.
MuruveDA. The innate immune response to adenovirus vectors. Hum Gene Ther, 2004; 15:1157–66.
4.
HensleySE, Giles-DavisW, McCoyKC, et al.Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol, 2005; 175:6032–6041.
5.
TatsisN, ErtlHC. Adenoviruses as vaccine vectors. Mol Ther, 2004; 10:616–629.
6.
XiangZQ, GreenbergL, ErtlHC, et al.Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology, 2014; 450–451:243–249.
7.
BarnesE, FolgoriA, CaponeS, et al.Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med, 2012; 4:115ra1.
8.
XiangK, YingG, YanZ, et al.Progress on adenovirus-vectored universal influenza vaccines. Hum Vaccin Immunother, 2015; 11:1209–1222.
9.
De SantisO, AudranR, PothinE, et al.Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis, 2016; 16:311–320.
10.
KhanamS, PilankattaR, KhannaN, et al.An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine, 2009; 27:6011–6021.
11.
DengG, LiW, WuX, et al.Immunogenicity and protective efficacy of a recombinant adenoviral based vaccine expressing heat-stable enterotoxin (STa) and K99 adhesion antigen of enterotoxigenic Escherichia coli in mice. Mol Immunol, 2015; 68:684–691.
12.
AlyahyaSA, NolanST, SmithCM, et al.Immunogenicity without efficacy of an adenoviral tuberculosis vaccine in a stringent mouse model for immunotherapy during treatment. PLoS One, 2015; 10:e0127907.
13.
TeixeiraLH, TararamCA, LasaroMO, et al.Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents. Infect Immun, 2014; 82:793–807.
14.
VasconcelosJR, DominguezMR, NevesRL, et al. Adenovirus vector-induced CD8+ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi infection. Hum Gene Ther, 2014; 25:350–363.
15.
ZhangY, ErtlHC. The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion. J Immunol, 2014; 193:1836–46.
16.
WangY, ZhangJ, WuY, et al.Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine. Sci Rep, 2015; 5:11275.
17.
Gomez-GutierrezJG, ElpekKG, Montes de Oca-LunaR, et al.Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother, 2007; 56:997–1007.
18.
WindheimM, HilgendorfA, BurgertHG. Immune evasion by adenovirus E3 proteins: exploitation of intracellular trafficking pathways. Curr Top Microbiol Immunol, 2004; 273:29–85.
19.
LichtensteinDL, TothK, DoroninK, et al.Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol, 2004; 23:75–111.
20.
BettAJ, PrevecL, GrahamFL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol, 1993; 67:5911–5921.
21.
SantraS, SunY, Korioth-SchmitzB, et al.Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine, 2009; 27:5837–5845.
22.
LiangX, CasimiroDR, SchleifWA, et al.Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol, 2005; 79:12321–12331.
23.
BarouchDH, AlterG, BrogeT, et al.Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science, 2015; 349:320–324.
24.
HaytonEJ, RoseA, IbrahimsaU, et al.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One, 2014; 9:e101591.
25.
BuchbinderSP, MehrotraDV, DuerrA, et al.Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 2008; 372:1881–1893.
26.
SaundersKO, PeguA, GeorgievIS, et al.Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J Virol, 2015; 89:5895–903.
27.
KarasavvasN, BillingsE, RaoM, et al.The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses, 2012; 28:1444–1457.
28.
GordonSN, DosterMN, KinesRC, et al.Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunol, 2014; 193:6172–6183.
29.
JoshiA, LeeRT, MohlJ, et al.Genetic signatures of HIV-1 envelope-mediated bystander apoptosis. J Biol Chem, 2014; 289:2497–2514.
30.
ZhouD, ZhouX, BianA, et al.An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc, 2010; 5:1775–1785.
31.
Gomez-RomanVR, CaoC, BaiY, et al.Phage-display mimotopes recognizing a biologically active anti-HIV-1 gp120 murine monoclonal antibody. J Acquir Immune Defic Syndr, 2002; 31:147–153.
32.
DickeyC, ZiegnerU, AgadjanyanMG, et al.Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization. DNA Cell Biol, 2000; 19:243–252.
33.
LeskowitzR, FoggMH, ZhouXY, et al.Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques. J Virol, 2014; 88:4721–4735.
34.
CervasiB, CarnathanDG, SheehanKM, et al.Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing the simian immunodeficiency virus Gag/Tat fusion protein and challenged intrarectally with repeated low doses of SIVmac. J Virol, 2013; 87:9420–9430.
35.
PintoAR, FitzgeraldJC, Giles-DavisW, et al.Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol, 2003; 171:6774–6779.
36.
TollefsonAE, YingB, DoroninK, et al.Identification of a new human adenovirus protein encoded by a novel late l-strand transcription unit. J Virol, 2007; 81:12918–12926.
37.
TatsisN, FitzgeraldJC, Reyes-SandovalA, et al.Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood, 2007; 110:1916–1923.
38.
ChenH, XiangZQ, LiY, et al.Adenovirus-based vaccines: comparison of vectors from three species of Adenoviridae. J Virol, 2010; 84:10522–10532.
39.
XiangZ, LiY, CunA, et al.Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis, 2006; 12:1596–1599.
40.
MassieB, CoutureF, LamoureuxL, MosserDD, GuilbaultC, JolicoeurP, BélangerF, LangelierY. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol, 1998; 72:2289–2296.
BurgertHG, BluschJH. Immunomodulatory functions encoded by the E3 transcription unit of adenoviruses. Virus Genes, 2000; 21:13–25.
43.
BenedictCA1, NorrisPS, PrigozyTI, BodmerJL, MahrJA, GarnettCT, MartinonF, TschoppJ, GoodingLR, WareCF. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and −2. J Biol Chem, 2001; 276:3270–3278.
44.
AlterG, MoodyMA. The humoral response to HIV-1: new insights, renewed focus. J Infect Dis, 2010; 202:S315–322.
45.
KarasavvasN, BillingsE, RaoM, et al.The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses, 2012; 28:1444–1457.
